We propose a 5-year renewal of the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), a consortia of the two leading sister campuses within the University System of Maryland, and the Food and Drug Administration (FDA). M-CERSI leverages the biomedical and health outcomes strengths in Baltimore with the engineering and technologies strengths in College Park.
Aims i nclude: Establish core program infrastructure and management plan to ensure success; Conduct regulatory science research; and Provide regulatory science training/educational programs. Proposed research projects align with FDA high priority topics, develop and evaluate methods to improve quality and safety, and/or develop methods and tools to improve and streamline clinical and post-market evaluation. Research is collaborative with FDA scientists and employs a vast array of research capabilities at UM. Research is amplified by a robust training/educational program, which includes lectures, workshops, scholars program, and the America's Got Regulatory Science Talent Competition. The sum of these activities describe a vibrant, cutting edge Center that stimulates innovative thought, disseminates understanding of regulatory sciences and practices, and generates new knowledge in support of the FDA's fundamental mission ? to promote and protect the public health.

Public Health Relevance

Statement We propose continuation of M-CERSI that fosters FDA-oriented research, as well as training/educational programs. The Center's mission is to foster the development of regulatory science ? the science of developing new tools, standards and approaches to assess the safety, efficacy, quality and performance of FDA-regulated products. Activities leverage the close geographic proximity between University of Maryland and FDA's main campus.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01FD005946-03
Application #
9712425
Study Section
Special Emphasis Panel (ZFD1)
Program Officer
Blumkemelor, Donna
Project Start
2016-09-15
Project End
2023-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Guo, Dong; Yang, Hong; Li, Qing et al. (2018) Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharm Res 35:204
Gaitonde, Priyanka; Bozzi, Laura M; Shaya, Fadia T (2018) Factors associated with use of disease modifying agents for rheumatoid arthritis in the National Hospital and Ambulatory Medical Care Survey. Semin Arthritis Rheum 47:649-653
Zhu, Peng; Ye, Zhi; Guo, Dong et al. (2018) Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). Pharm Res 35:243
Deshpande, Tanvi M; Shi, Helen; Pietryka, John et al. (2018) Investigation of Polymer/Surfactant Interactions and Their Impact on Itraconazole Solubility and Precipitation Kinetics for Developing Spray-Dried Amorphous Solid Dispersions. Mol Pharm 15:962-974
Mackowiak, Bryan; Li, Linhao; Welch, Matthew A et al. (2017) Molecular Basis of Metabolism-Mediated Conversion of PK11195 from an Antagonist to an Agonist of the Constitutive Androstane Receptor. Mol Pharmacol 92:75-87
Oner, Z Gulsen; Michel, Sarah L J; Polli, James E (2017) Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey. Ann N Y Acad Sci 1407:26-38
Ali, Izna; Welch, Matthew A; Lu, Yang et al. (2017) Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay. Eur J Pharm Sci 103:52-59
Dong, Zhongqi; Li, Qing; Guo, Dong et al. (2015) Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. J Pharm Sci 104:2864-76
Dong, Zhongqi; Ekins, Sean; Polli, James E (2015) A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide. Int J Pharm 478:88-95
Dong, Zhongqi; Ekins, Sean; Polli, James E (2015) Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. Eur J Pharm Sci 66:1-9

Showing the most recent 10 out of 29 publications